Unlock instant, AI-driven research and patent intelligence for your innovation.

A fully human monoclonal antibody against novel coronavirus and its application

A monoclonal antibody, coronavirus technology, applied in antiviral agents, antiviral immunoglobulins, antibodies, etc., can solve the problems of difficult large-scale preparation, the risk of disease transmission between batches, and the limited source of plasma for recovered patients. good stability

Active Publication Date: 2021-08-03
SUZHOU YUZHIBO BIOLOGICAL TECH CO LTD
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the limited source of plasma from recovered patients, it is difficult to prepare on a large scale, and there are factors such as batch-to-batch differences and risks of other disease infections, making this therapy unable to be widely used.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A fully human monoclonal antibody against novel coronavirus and its application
  • A fully human monoclonal antibody against novel coronavirus and its application
  • A fully human monoclonal antibody against novel coronavirus and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Example 1: Screening and preparation of fully human anti-new coronavirus monoclonal antibody

[0035] 1.1 Labeling of probes

[0036] The required SARS-CoV2-related specific positive and negative probes are conjugated with fluorescent dyes, and the process is as follows:

[0037] 1.1.1 AviTag fusion protein biotinylation kit (Avidity, BirA500) was used for biotin labeling of probes. The reaction system was prepared according to the steps described in the manual, and incubated at 30 °C for 30 min.

[0038] 1.1.2 Use a 30 kDa ultrafiltration tube to exchange the reaction product with 1× PBS (pH 7.4) to remove excess biotin.

[0039] 1.1.3 Gradually add 1 / 5 molar equivalent of streptavidin-phycoerythrin (SA-PE) or streptavidin-allophycocyanin (SA-APC) to the biotin label at intervals of 20 min until the molar ratio of SA-PE or SA-APC to biotin-labeled probe reached 1:1, and incubated at 4 °C with gentle shaking to prepare positive and negative probes labeled with fluore...

Embodiment 2

[0075] Example 2: Analysis of the binding activity of monoclonal antibody YK-CoV-02 to RBD protein

[0076] Antibody-antigen binding activity analysis using Gator label-free biomolecular analyzer

[0077] 2.1. GNTi cells were used to express RBD, and after purification by nickel column and molecular sieve, RBD was biotinylated according to the steps indicated in the instructions of DSB-X™ Biotin Protein Labeling Kit (Invitrogen™, D20655).

[0078] 2.2 The biotinylated RBD was diluted 600 times, 3 μL of RBD was added to 2000 μl of HBS-EP buffer and mixed, and the diluted RBD was loaded into a 96-well sample plate at an amount of 200 μL per well.

[0079] 2.3 Use HRV 3C protease to cut the monoclonal antibody into Fab fragments, use affinity chromatography and molecular sieve to purify the obtained antibody Fab, after diluting the antibody Fab by 1000 times, continue to perform gradient dilution according to 1:3, a total of 4 dilutions (36.2nM, 12.1 nM, 4.02 nM and 1.34 nM), ta...

Embodiment 3

[0084] Example 3: Analysis of the ability of monoclonal antibody YK-CoV-02 to competitively block the binding of RBD to the receptor ACE2

[0085] Analysis of Antibody Blocking Binding Ability of SARS-CoV2 Virus RBD and Receptor ACE2 Using Gator Non-labeled Biomolecular Analyzer

[0086] 3.1 Expi-CHO cells were used to express the receptor ACE2, and after purification by nickel column and molecular sieve, ACE2 was biotinylated according to the steps shown in the instructions of DSB-X™ Biotin Labeling Kit (Invitrogen™, D20655). The biotinylated ACE2 was diluted to 40 μg / mL with a molar concentration of 570 nM.

[0087] 3.2 Dilute RBD to 30 μg / mL, the molar concentration is 1000 nM, dilute the antibody to 0.2 mg / mL, and mix with RBD at a molar ratio of 1:1. The molar amount of antibody in the prepared mixture is greater than that of ACE2 .

[0088] 3.3 During the detection process, each experiment was first equilibrated in the HBS-EP buffer of the probe card for 120 s, and the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of biomedicine, and discloses a fully human monoclonal antibody against novel coronavirus and its application. Using the SARS‑CoV2 receptor binding domain (RBD) as a probe, flow cytometry was used to screen B lymphocytes from recovered patients with new coronary pneumonia, and the affinity constant of monoclonal antibody to RBD was 4.03 nM. Using X-ray crystallography to analyze the three-dimensional structure of the antibody-RBD complex, it was found that the binding epitope of the antibody and the host cell receptor (ACE2) overlapped, which could competitively block the binding of RBD and ACE2, inhibit the virus from infecting the host cell, and also In response to certain genetic mutations of the new coronavirus, the half effective concentration (IC) that blocks the infection of host cells by the pseudovirus (accumulated B. 50 ) is 0.12 ng / mL, and has application prospects in the diagnosis, treatment and prevention of new coronary pneumonia.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a fully human monoclonal antibody against novel coronavirus and its application. Background technique [0002] The causative agent of novel coronavirus pneumonia (COVID-19) is a novel coronavirus (SARS-CoV2), which can cause severe acute respiratory disease. According to the report of the World Health Organization, the epidemic has spread to 216 countries and regions, causing a large number of casualties. Clinical features of COVID-19 include fever, dry cough and fatigue, respiratory failure, and even death. So far, most of the vaccines used for prevention and specific drugs for the treatment of novel coronavirus pneumonia are still in the stage of clinical trials or emergency use under specific conditions, and their safety and effectiveness need to be further verified. [0003] SARS-CoV2 belongs to the genus Coronavirus of the Coronaviridae family, and is a class of envelo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/10C12N15/13A61K39/42A61P31/14G01N33/577G01N33/569
CPCA61P31/14C07K16/10C07K2317/56C07K2317/76C07K2317/92G01N33/56983G01N33/577G01N2333/165G01N2469/10
Inventor 陈磊高腾森戴敏张冀王聪赵氏璧谢欣周翔宇王得荣陈莉周臣飞
Owner SUZHOU YUZHIBO BIOLOGICAL TECH CO LTD
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com